Patients with histologically confirmed MAIPC

Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone

If LHRH agonist were used previously it must be kept

Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida

Previous DES should be held for at least 4 weeks before partcipating in the trial

Chemotherapy naive patients

No prior radioisotope

Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy

KPS\> 70%

Adequate hematologic, hepatic and renal function

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer